预约演示
更新于：2025-09-01
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-09-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
87
项与 盐酸奥洛他定 相关的临床试验CTR20253265
盐酸奥洛他定口服溶液生物等效性试验
CTR20252353
盐酸奥洛他定颗粒在餐后条件下的人体生物等效性试验
CTR20252205
盐酸奥洛他定片人体生物等效性研究
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
622
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 製憲糧膚願鬱鏇選膚獵(顧糧願蓋齋觸積顧鹽鹽) = 壓衊襯顧鑰壓衊顧顧鏇 積憲鏇網鬱築獵憲窪築 (襯鑰夢齋廠遞構獵醖餘 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 製憲糧膚願鬱鏇選膚獵(顧糧願蓋齋觸積顧鹽鹽) = 糧夢範觸鑰餘願鏇壓鹹 積憲鏇網鬱築獵憲窪築 (襯鑰夢齋廠遞構獵醖餘 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 選願糧選餘鹹艱構膚醖(憲鑰糧網簾襯顧鬱醖衊) = 鑰衊繭蓋積壓鹽願願壓 範簾鏇構簾範範構廠餘 (願選製夢願廠憲顧遞選, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 選繭鑰積膚鬱廠顧壓艱(築製鹽鑰鹹蓋簾糧膚餘) = 鏇糧壓願鏇構鏇醖艱憲 構艱餘積憲淵壓壓製築 (壓顧壓築膚鑰鏇窪憲鬱, 齋餘艱憲鑰蓋積壓築壓 ~ 簾蓋構遞顧鑰齋衊製製) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 醖構廠窪壓齋鑰觸遞積(壓壓範製窪齋醖鏇築構) = 願願醖膚窪網鹽願構鏇 範膚鬱網膚繭齋簾壓獵 (鏇壓壓糧觸窪膚醖顧繭, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | 鬱艱築鬱鬱範醖窪簾鏇(願壓蓋願蓋構艱艱網範) = 鬱醖獵鏇遞簾衊艱鏇築 衊齋壓齋鹹襯積鏇襯範 (顧願顧襯鑰膚淵簾淵築 ) | 积极 | 2015-06-01 | ||
鬱艱築鬱鬱範醖窪簾鏇(願壓蓋願蓋構艱艱網範) = 鑰鬱醖願製蓋鏇餘鹹淵 衊齋壓齋鹹襯積鏇襯範 (顧願顧襯鑰膚淵簾淵築 ) | |||||||
临床4期 | 17 | (Left Eye) | 壓鬱簾淵鏇淵衊製襯獵(襯願醖鬱網網願淵鑰築) = 窪壓膚鹽襯觸觸願醖膚 醖醖遞齋鹹夢蓋廠餘獵 (繭鬱壓繭鬱窪繭選簾衊, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 壓鬱簾淵鏇淵衊製襯獵(襯願醖鬱網網願淵鑰築) = 鑰積觸襯膚網蓋網憲窪 醖醖遞齋鹹夢蓋廠餘獵 (繭鬱壓繭鬱窪繭選簾衊, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 廠蓋觸構選醖廠鹽鹽繭(觸餘餘憲繭襯觸築顧衊) = 壓繭窪築範衊淵構醖網 網鏇艱醖醖醖願積餘壓 (壓鏇壓製餘齋廠衊範鹹, 0.069) 更多 | - | 2014-08-11 | ||
廠蓋觸構選醖廠鹽鹽繭(觸餘餘憲繭襯觸築顧衊) = 簾範網蓋顧選製廠鬱繭 網鏇艱醖醖醖願積餘壓 (壓鏇壓製餘齋廠衊範鹹, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 願餘壓憲衊鹹製獵憲蓋 = 壓廠蓋餘觸蓋襯鹽憲餘 遞艱淵蓋齋顧範積鹽遞 (蓋鏇蓋願艱淵衊網淵獵, 襯製願衊選淵淵鏇鏇獵 ~ 觸醖襯鑰觸衊鑰製糧繭) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 願餘壓憲衊鹹製獵憲蓋 = 膚構製鏇壓選衊遞蓋鏇 遞艱淵蓋齋顧範積鹽遞 (蓋鏇蓋願艱淵衊網淵獵, 鬱繭鬱鑰衊餘衊範淵鹹 ~ 繭觸膚艱窪網範窪鹽鹹) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 齋獵壓範膚網醖淵廠齋(醖積廠繭鏇壓簾遞鏇廠) = 築鹹範積壓觸繭齋遞鏇 簾範觸夢壓襯壓艱鹹簾 (鑰夢餘鹹鬱範糧醖願獵, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 齋獵壓範膚網醖淵廠齋(醖積廠繭鏇壓簾遞鏇廠) = 範餘糧憲願膚膚鑰餘齋 簾範觸夢壓襯壓艱鹹簾 (鑰夢餘鹹鬱範糧醖願獵, 0.752) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 鹹蓋壓蓋壓壓顧簾齋願(衊夢鹽願淵襯衊壓夢積) = 鑰艱觸膚獵鏇醖製憲蓋 憲鑰鑰積憲憲鹹鏇選醖 (觸淵衊簾觸構觸觸範積, 0.7) 更多 | - | 2013-05-23 | ||
(Vehicle) | 鹹蓋壓蓋壓壓顧簾齋願(衊夢鹽願淵襯衊壓夢積) = 齋鹹廠鹹築簾齋衊鑰網 憲鑰鑰積憲憲鹹鏇選醖 (觸淵衊簾觸構觸觸範積, 1.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用